Akebia Therapeutics has spun off a new company, the similarly named Aerpio Therapeutics, to develop drugs for diabetic macular edema and inflammatory bowel disease.
Akebia will continue developing its oral anemia drug candidate, according to a statement from the Cincinnati-area company.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The new company is looking to raise a series A round of financing this year.
“The formation of Aerpio allows us to focus and attract resources to the substantial opportunity we believe our lead programs represent,” said Joseph Gardner, CEO of both companies.
Aerpio plans to begin a phase 2a trial of its lead candidate, the diabetic macular edema drug, in the second quarter. The disease involves the swelling of the retina due to fluid leakage from blood vessels within the central portion of the retina.
Akebia last year raised a $22 million series B round to support clinical trials of its anemia drug. The round was led by Novartis Venture Fund and Venture Investors, and featured participation from a number of other investors.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Akebia was started several years ago after acquiring the rights to two drugs from Procter & Gamble, which dismantled its pharmaceuticals division.
